IPW
TGTX icon

Impact Partnership Wealth’s TG Therapeutics TGTX Stock Holding History

Impact Partnership Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,964
Closed -$252K – 426
2025
Q3 		$252K Buy
+6,964
New +$229K 0.04% 252
2023
Q3 		– Sell
-167
Closed -$4.15K – 1199
2023
Q2 		$4.15K Buy
+167
New +$4.31K ﹤0.01% 535

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Impact Partnership Wealth's TGTX Position: Q4 2025 in Review

Impact Partnership Wealth sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 6,964 shares — an estimated $252K sold.

Impact Partnership Wealth first reported a position in TGTX in Q2 2023 and held it in 2 quarters. The position peaked at $252K in Q3 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Impact Partnership Wealth reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Impact Partnership Wealth sold 6,964 TG Therapeutics shares in Q4 2025, an estimated $252K.
  • Impact Partnership Wealth first reported a position in TG Therapeutics in Q2 2023 and held it in 2 quarters.
  • Impact Partnership Wealth's TG Therapeutics position peaked at $252K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Impact Partnership Wealth's 13F filing for Q4 2025, filed 10 Feb 2026.